2011
Long-Term Lyme Disease Antibiotic Therapy Beliefs Among New England Residents
Macauda MM, Erickson P, Miller J, Mann P, Closter L, Krause PJ. Long-Term Lyme Disease Antibiotic Therapy Beliefs Among New England Residents. Vector-Borne And Zoonotic Diseases 2011, 11: 857-862. PMID: 21417921, DOI: 10.1089/vbz.2010.0116.Peer-Reviewed Original ResearchConceptsLyme diseasePersistent symptomsAntibiotic treatmentEffective doctor-patient communicationAntibiotic therapy regimensInfectious Diseases SocietyLong-term treatmentBorrelia burgdorferi infectionDoctor-patient communicationFederal health agenciesDiseases SocietyAppropriate therapyTherapy regimensAntimicrobial therapyBurgdorferi infectionHealthcare workersMost physiciansStandard diagnosisDisease controlDiseasePatientsHealth agenciesSymptomsPhysiciansMedical societies
2009
Update on Babesiosis
Vannier E, Krause PJ. Update on Babesiosis. Interdisciplinary Perspectives On Infectious Diseases 2009, 2009: 984568. PMID: 19727410, PMCID: PMC2734943, DOI: 10.1155/2009/984568.Peer-Reviewed Original ResearchTick-borne infectious diseaseHuman babesiosisBlood safety riskSpecific antimicrobial therapyMultiple prevention strategiesFulminant diseaseThin blood smearsClinical featuresExchange transfusionModerate illnessImmunosuppressive drugsAsymptomatic infectionDefinitive diagnosisAsymptomatic carriersAntimicrobial therapyConvalescent seraSevere diseaseImmunocompromised individualsHigh riskSevere casesEndemic areasPrevention strategiesBabesia antibodiesHealthy adultsInfection range
2008
Persistent and Relapsing Babesiosis in Immunocompromised Patients
Krause PJ, Gewurz BE, Hill D, Marty FM, Vannier E, Foppa IM, Furman RR, Neuhaus E, Skowron G, Gupta S, McCalla C, Pesanti EL, Young M, Heiman D, Hsue G, Gelfand JA, Wormser GP, Dickason J, Bia FJ, Hartman B, Telford SR, Christianson D, Dardick K, Coleman M, Girotto JE, Spielman A. Persistent and Relapsing Babesiosis in Immunocompromised Patients. Clinical Infectious Diseases 2008, 46: 370-376. PMID: 18181735, DOI: 10.1086/525852.Peer-Reviewed Original ResearchConceptsCase patientsAntibabesial treatmentClinical courseControl subjectsBlood smearsRetrospective case-control studyOptimal treatment regimenStandard antimicrobial therapyMalaria-like illnessBabesia microti infectionMost cases patientsCase-control studyCourse of therapyB-cell lymphomaAdministration of atovaquoneImmunologic statusStandard therapyAntimicrobial regimenSuch patientsTreatment regimenMicroti infectionAntimicrobial therapyPersistent infectionCell lymphomaAcute babesiosis
2006
The Clinical Assessment, Treatment, and Prevention of Lyme Disease, Human Granulocytic Anaplasmosis, and Babesiosis: Clinical Practice Guidelines by the Infectious Diseases Society of America
Wormser GP, Dattwyler RJ, Shapiro ED, Halperin JJ, Steere AC, Klempner MS, Krause PJ, Bakken JS, Strle F, Stanek G, Bockenstedt L, Fish D, Dumler JS, Nadelman RB. The Clinical Assessment, Treatment, and Prevention of Lyme Disease, Human Granulocytic Anaplasmosis, and Babesiosis: Clinical Practice Guidelines by the Infectious Diseases Society of America. Clinical Infectious Diseases 2006, 43: 1089-1134. PMID: 17029130, DOI: 10.1086/508667.Peer-Reviewed Original ResearchConceptsInfectious Diseases SocietyHuman granulocytic anaplasmosisDiseases SocietyLyme diseasePost-Lyme disease syndromeGranulocytic anaplasmosisPrevious treatment guidelinesManagement of patientsClinical practice guidelinesEvidence-based guidelinesHealth care providersTickborne infectionTreatment guidelinesClinical manifestationsAntimicrobial therapyClinical assessmentPractice guidelinesCare providersDisease syndromeExpert panelDiseasePreventionPatientsTherapyInfection